StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Erbitux (cetuximab) — U.S. revenue [legacy] by Quarter

Erbitux (cetuximab) — U.S. revenue ($M) [legacy] ($M)

QuarterlyAnnual

Eli Lilly Erbitux (cetuximab) — U.S. revenue [legacy]: $154M in Q4 2024, up 17.8% from a year earlier. That is the highest of the 32 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
154
Period ended Dec 31, 2024
Change on a year earlier
+17.8%
131 in Q4 2023
History
32 quarters
Since Q1 2017
Sources
27
Documents cited below

Where the Q4 2024 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2025-02-19) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedErbitux (cetuximab) — U.S. revenue ($M) [legacy] ($M)Year on yearSource
Q4 2024Dec 31, 2024154+17.8%Form 10-K (filed 2025-02-19) ↗
Q3 2024Sep 30, 2024133-0.6%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024143-1.8%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024132+11.2%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023131-6.1%Form 10-K (filed 2025-02-19) ↗
Q3 2023Sep 30, 2023134+6.1%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023146+16.3%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023119+8.3%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022139+12.1%Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 2022126+10.8%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022125-7.9%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 2022110+1.7%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 2021124+0.1%Form 10-K (filed 2024-02-21) ↗
Q3 2021Sep 30, 2021114-6.9%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021136+17.3%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021108-8.4%Form 10-Q (filed 2022-04-29) ↗

Cite this data

StockData. (2026). Eli Lilly Erbitux (cetuximab) — U.S. revenue [legacy] ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-erbitux-us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.